Viking Therapeutics' stock fell 15% after it priced an upsized $500 million offering of common stock and convertible notes, diluting existing shares despite recent positive clinical news. Jaguar Health's shares dropped 25% with no new disclosures, likely due to its small market cap and recent reverse stock split. These moves reflect company-specific factors rather than sector-wide trends, as the biotech sector and broader market showed mixed but stable performance. Investors should watch how Viking's stock absorbs the new supply and monitor any updates from Jaguar Health, treating both as high-risk, volatile positions.
Viking Therapeutics and Jaguar Health are the subjects of this market update. For readers following the health sector, here is Pluang's market snapshot as of Sep 24, 2026 20:44 WIB: out of 100 priced health-sector US stocks, 50 rose and 47 fell. Notable movers include TransMedics Group Inc at USD 84.50 with a 1-day change of -2.87%, Oscar Health Inc at USD 29.72 down 2.65%, and AbCellera Biologics Inc at USD 12.00 down 2.52%.
Analysts have mixed views on VICI Properties, a REIT focused on gaming and hospitality properties, with some lowering price targets due to refinancing costs and rent growth limits. Despite these concerns, the company maintains strong fundamentals inc...
Roth Capital upgraded Okta's price target from $155 to $235 and maintained a Buy rating following the company's new AI agent identity strategy unveiled at its Investor Summit. Okta aims to expand beyond traditional identity management by securing AI ...
Vecima Networks reported strong quarterly results with revenue of $64.04 million, surpassing the $55.69 million estimate, and earnings per share of $0.15, beating the $0.14 forecast. The company, a broadband technology provider for cable and fiber op...
Bank of America raised its price target for Okta Inc to $220 from $200 following the company's announcement of new AI-agent security and identity features at the Oktane 2026 conference. These enhancements include Agent SSO, runtime enforcement, and s...
Jefferies reaffirmed its $110 price target on Uber Technologies, highlighting the company's expanding Mobility product suite as a key driver for faster bookings growth and margin expansion. The broker expects Uber's adjusted EBITDA to grow over 25% t...
